KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Expenses (2016 - 2025)

Neogenomics (NEO) has disclosed Operating Expenses for 16 consecutive years, with $96.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 1.15% year-over-year to $96.8 million, compared with a TTM value of $430.2 million through Dec 2025, up 12.55%, and an annual FY2025 reading of $430.2 million, up 12.55% over the prior year.
  • Operating Expenses was $96.8 million for Q4 2025 at Neogenomics, down from $107.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $124.9 million in Q2 2025 and bottomed at $56.7 million in Q1 2021.
  • Average Operating Expenses over 5 years is $90.8 million, with a median of $89.8 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 76.03% in 2021, then fell 4.16% in 2022.
  • Year by year, Operating Expenses stood at $86.8 million in 2021, then dropped by 4.16% to $83.2 million in 2022, then grew by 3.55% to $86.2 million in 2023, then rose by 11.02% to $95.7 million in 2024, then grew by 1.15% to $96.8 million in 2025.
  • Business Quant data shows Operating Expenses for NEO at $96.8 million in Q4 2025, $107.5 million in Q3 2025, and $124.9 million in Q2 2025.